Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × talazoparib × Clear all

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 4 Ovarian Neoplasms 3 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Adenocarcinoma 1 Advanced Breast Cancer 1

Interventions

Bevacizumab 209 Fluorouracil 199 Irinotecan 192 Oxaliplatin 190 Leucovorin 179 Capecitabine 133 Cetuximab 129 Panitumumab 62 Folfox protocol 45 regorafenib 39 Radiotherapy 37 IFL protocol 35 pembrolizumab 34 HMPL-013 31 trifluridine tipiracil drug combination 28 Nivolumab 27 Neoadjuvant Therapy 24 Drug Therapy 22 tislelizumab 16 Celecoxib 16 aflibercept 15 XELOX 15 Chemotherapy, Adjuvant 15 Trifluridine 14 sintilimab 13 durvalumab 13 atezolizumab 13 Trastuzumab 13 Gemcitabine 13 Floxuridine 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡